doi:10.3969/j.issn.1004-583X.2021.02.019

Abstract

CLC Number:

R733.7

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.019

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I2/188

References 35

[1]	苏州市疾病预防控制中心, 上海市疾病预防控制中心, 杭州市疾病预防控制中心, 等. 特殊健康状态儿童预防接种专家共识之十七——白血病化疗与预防接种[J]. 中国实用儿科杂志, 2019,34(4):266-267.
[2]	张培芬, 张玉明, 吴翠玲, 等. 儿童急性白血病合并感染的研究进展[J]. 实用医学杂志, 2017,33(19):3159-3162.
[3]	陈再生, 郑灵, 陈以乔, 等. 儿童急性淋巴细胞白血病诱导缓解期感染的病原菌及耐药情况分析[J]. 中国当代儿科杂志, 2017,19(2):176-181.
[4]	Simona Z, Ondǐej H, Jana P, et al. Occurrence and antibiotic resistance of enterobacteriaceae in acute leukemia patients[J]. Klin Onkol, 2018,31(4):282-288.
[5]	张国香, 陕柏峰, 申徐良, 等. 急性白血病患者血培养阳性病原菌分布及耐药性分析[J]. 白血病·淋巴瘤, 2014,23(10):621-623.
[6]	巫一立, 余莉华, 林丹娜, 等. 儿童急性白血病多重耐药菌血流感染的临床特征和高危因素分析[J]. 中国实用儿科杂志, 2019,34(5):414-418.
[7]	Tumbarello M, Micozzi A, De Rosa FG. Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients[J]. J Chemother, 2015,27(4):250-252. doi: 10.1179/1973947814Y.0000000216 pmid: 25257205
[8]	Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients[J]. J Infect, 2014,68(4):321-331. doi: 10.1016/j.jinf.2013.12.006 URL
[9]	Nateghian A, Robinson JL, Arjmandi K, et al. Epidemiology of vancomycin-resistant enterococci in children with acute lymphoblastic leukemia at two referral centers in Tehran, Iran: a descriptive study[J]. Int J Infect Dis, 2011,15(5):e332-e335. doi: 10.1016/j.ijid.2011.01.006 URL
[10]	Silva ACBE, Anchieta LM, Rosado V, et al. Antimicrobial use for treatment of healthcare-associated infections and bacterial resistance in a reference neonatal unit[J]. J Pediatr (Rio J), 2020 Jun 24;S0021-7557(20): 30184-4. Online ahead of print.
[11]	袁晓宁. 多重耐药菌的形成机理及其防控措施研究进展[J]. 中国消毒学杂志, 2016,33(8):792-796.
[12]	Kömürcü B, Tükenmez Tigen E, Toptaᶊ T, et al. Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study[J]. Expert Rev Hematol, 2020,13(8):923-927. doi: 10.1080/17474086.2020.1787145 URL
[13]	Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes[J]. J Antimicrob Chemother, 2011,66(3):657-663. doi: 10.1093/jac/dkq494 URL
[14]	周芳, 董亚琳. ICU多重耐药菌医院感染的危险因素分析[J]. 中国药房, 2017,28(14):1916-1920.
[15]	丁元廷. 细菌耐药机制的国内外最新研究进展[J]. 现代预防医学, 2013,40(6):1109-1111.
[16]	杨继勇, 罗燕萍, 张有江. 质粒介导喹诺酮类耐药基因qnr研究进展[J]. 中华医院感染学杂志, 2012,22(22):5172-5174.
[17]	Kohler V, Vaishampayan A, Grohmann E. Broad-host-range Inc18 plasmids: Occurrence, spread and transfer mechanisms[J]. Plasmid, 2018,99:11-21. doi: 10.1016/j.plasmid.2018.06.001 URL
[18]	杨仁国, 吕晓菊. 整合子系统与细菌多重耐药研究进展[J]. 中国抗生素杂志, 2008,33(4):198-202.
[19]	唐慧琴, 陈定强, 吴爱武. 亚胺培南耐药铜绿假单胞菌I类整合子检测[J]. 实用医学杂志, 2017,33(9):1494-1497.
[20]	韩江雪, 刘忆霜, 肖春玲. β-内酰胺酶抑制剂研究进展[J]. 中国抗生素杂志, 2019,44(6):647-653.
[21]	黄支密, 夏守慧, 沈娟, 等. 携带blaKPC-2型碳青霉烯酶基因泛耐药肺炎克雷伯菌对喹诺酮类耐药机制研究[J]. 中华医院感染学杂志, 2015, (8):1684-1686, 1692.
[22]	李昕, 曾洁, 王岱, 等. 细菌耐药耐受性机制的最新研究进展[J]. 中国抗生素杂志, 2020,45(2):113-121.
[23]	杨凤春, 任爱民. 主动外排泵系统介导鲍氏不动杆菌多药耐药机制的研究进展[J]. 中华医院感染学杂志, 2012,22(11):2478-2480.
[24]	宋志军, 吴红, Michael Givskov, 等. 细菌生物膜与抗生素耐药[J]. 自然科学进展, 2003,13(10):1015-1021.
[25]	牛付轩, 吴亮, 王廷廷, 等. 临床分离鲍氏不动杆菌生物膜形成能力与耐药性关系研究[J]. 中华医院感染学杂志, 2018,28(18):2721-2724, 2730.
[26]	Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients[J]. Clin Microbiol Infect, 2014,20(Suppl 1):1-55.
[27]	黄勋, 邓子德, 倪语星, 等. 多重耐药菌医院感染预防与控制中国专家共识[J]. 中国感染控制杂志, 2015,14(1):1-9.
[28]	骆玉乔, 张玲, 马耀, 等. 医院多重耐药菌感染与筛查[J]. 中国消毒学杂志, 2013,30(12):1184-1185.
[29]	杨雅婷, 胡静, 王静, 等. 多重耐药菌感染患者隔离措施的防护效果[J]. 中国消毒学杂志, 2014,31(6):656-657.
[30]	李惠芬, 李松琴, 张苏明, 等. 环境清洁消毒标准化干预措施预防重症监护室多重耐药菌感染应用研究[J]. 中国消毒学杂志, 2016,33(6):594-596.
[31]	Gyssens IC, Kern WV, Livermore DM, et al. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients[J]. Haematologica, 2013,98(12):1821-1825. doi: 10.3324/haematol.2013.091769 pmid: 24323982
[32]	Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria[J]. Lancet Oncol, 2014,15(13):e606-e619. doi: 10.1016/S1470-2045(14)70344-4 URL
[33]	Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia[J]. Haematologica, 2013,98(12):1826-1835. doi: 10.3324/haematol.2013.091025 pmid: 24323983
[34]	Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2011,52(4):e56-e93. doi: 10.1093/cid/cir073 URL
[35]	李春富, 孙树梅. 儿童血液病多重耐药菌感染的治疗对策[J]. 中华实用儿科临床杂志, 2015,30(15):1124-1127.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Lili, Yuan Yuting, Lai Gengliang, Tian Chuan, Lan Xiang, Ye Zhonglv. The relationship between minimal residual disease on day 15 and prognosis in children with acute lymphoblastic leukemia [J]. Clinical Focus, 2024, 39(1): 47-52.
[2]	. [J]. Clinical Focus, 2023, 38(10): 954-960.
[3]	Dong Zhengrong, Tao Qianshan, Shen Yuanyuan, Dong Yi. Analysis of the follow-up results of 163 patients with acute promyelocytic leukemia [J]. Clinical Focus, 2023, 38(9): 813-818.
[4]	Du Jiayi, Liu Lili, He Yongzhong, Tian Chuan, Lan Xiang, Ye Zhonglyu. Clinical observation of serious adverse events in children with acute lymphoblastic leukemia during chemotherapy [J]. Clinical Focus, 2023, 38(2): 149-154.
[5]	Yin Lingling, Wu Wenjian, Zhu Feng. Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(11): 1025-1030.
[6]	Shen Ziyuan, Kang Haiquan, Sang Wei, Yan Dongmei. Analysis of bacterial distribution, resistance and risk factor of death of bacterial infection in leukemia patients [J]. Clinical Focus, 2021, 36(12): 1092-1096.
[7]	Ma Rui, Sun Yuqian. Standardized treatment of acute leukemia by haplo-identical stem cell transplantation [J]. Clinical Focus, 2021, 36(10): 869-873.
[8]	Lu Wenyi, Zhao Mingfeng. The standard treatment of acute lymphoblastic leukemia [J]. Clinical Focus, 2021, 36(10): 874-879.
[9]	Liu Qiaoxue, Wei Hui. Standardized treatment of acute myeloid leukemia [J]. Clinical Focus, 2021, 36(10): 880-883.
[10]	Qin Yazhen. Standardized detection of BCR-ABL mRNA and clinical application in patients with chronic myeloid leukemia [J]. Clinical Focus, 2021, 36(10): 884-888.
[11]	Wang Hui, Chen Man. Flow cytometry in minimal residual disease detection of acute myeloid leukemia: current status and progress [J]. Clinical Focus, 2021, 36(10): 889-895.
[12]	Liu Jianning, Sun Li, Niu Zhiyun, Wen Shupeng, Wang Ying, Zhang Xuejun, Wang Fuxu. Expression of PD-1 on T-lymphocytes in acute leukemia after allogeneic hematopoietic stem cell transplantation [J]. Clinical Focus, 2021, 36(3): 251-255.
[13]	Ren Jinhai;Guo Xiaoling;Cai Shengxin. Diagnosis and treatment of relapsed/refractory acute myeloid leukemia [J]. Clinical Focus, 2015, 30(10): 1100-1103.
[14]	Guo Xiaonan;Qiao Shukai. Standardized management of tyrosine kinase inhibitors therapy for patients with chronic myelogenous leukemia in clinic [J]. Clinical Focus, 2015, 30(10): 1104-1109.
[15]	Xiong Shudao;Hu Linhui;Pu Lianfang;Wang Huiping;Zhang Chui;Yang Dongdong;Zhai Zhimin. Acute leukemia with FUS/ERG fusion gene: three cases report and literature review [J]. Clinical Focus, 2015, 30(10): 1126-1129.